Previous 10 | Next 10 |
2023-07-18 09:50:16 ET Cathie Wood is one of the most successful investors of our time. Her flagship fund, Ark Innovation ETF (NYSEMKT: ARKK) , has already delivered a market-beating 59% return on capital so far this year. At its peak less than two years ago, the fund was up by over...
2023-07-15 04:25:01 ET Summary The memo reads that the bear market has been cancelled, and there are few who are as happy about the change in fortunes as Cathie Wood and ARK Funds. Her flagship ARKK fund, as well as other ARK family funds, have had an impressive run lately and wer...
Exact Sciences schedules second quarter 2023 earnings call PR Newswire MADISON, Wis. , July 10, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to relea...
2023-06-28 09:53:00 ET It's been a good start to the year for Cathie Wood's ARK Innovation ETF , which is up 36% thus far in 2023. The fund has benefited as growth stocks have been getting back into the good graces of investors thanks partly to excitement over artificial intelligence as...
2023-06-22 09:53:00 ET The stock market can move in any direction over a year, and it is difficult to predict which way it will go. But over more extended periods, say, a decade, equities tend to be northbound. That doesn't mean just any old company will do the trick for investors looking t...
2023-06-22 08:00:00 ET Summary Exact Sciences' next-generation Cologuard test shows improved specificity, cancer sensitivity, and precancer sensitivity, which could lead to better insurance coverage and increased reimbursements. The successful BLUE-C study and potential FDA approv...
Exact Sciences Advances Innovative Cancer Technologies and Approaches Through Visionary Collaborations PR Newswire Agreements with Broad Institute of MIT and Harvard provide exclusive license to next-generation technology for ultra-sensitive detection of molecular resi...
Next-generation Cologuard Test Demonstrates 94 Percent Sensitivity for Colorectal Cancer at 91 Percent Specificity, Raising the Bar in Non-invasive Screening PR Newswire BLUE-C study met all endpoints, showing improved cancer sensitivity, specificity, and precancer sensit...
2023-06-07 08:00:00 ET Cancer screening specialist Exact Sciences (NASDAQ: EXAS) is on fire. The company's shares have soared 69% since 2023 started. Gains of this magnitude can sometimes scare off investors who see limited upside left for the company in question. But in the case of...
2023-06-06 02:59:44 ET Summary AI development has potential to create job losses, new jobs, and enhance current jobs, with early winners, including Nvidia, Microsoft, and Alphabet. Downstream beneficiaries of AI include businesses that can reduce headcount or accelerate growth, su...
News, Short Squeeze, Breakout and More Instantly...
Exact Sciences Corporation Company Name:
EXAS Stock Symbol:
NASDAQ Market:
Exact Sciences Corporation Website:
2024-07-11 08:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-08 08:30:00 ET To say that Exact Sciences (NASDAQ: EXAS) hasn't performed well on the stock market this year would be an understatement. Shares of the cancer-focused biotech are down by 41%. However, the healthcare company still has some fans on Wall Street. Cathie Wood ...
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2024 financial results after the close of the U.S. financial markets on July 31, 2024. Following the release, company management w...